USA flag logo/image

An Official Website of the United States Government

Mass Spectrometric Immunoassay of Apolipoproteins

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65633
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
HL072671
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
INTRINSIC BIOPROBES, INC.
2155 E CONFERENCE DR STE 104 TEMPE, AZ 85284-2604
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2003
Title: Mass Spectrometric Immunoassay of Apolipoproteins
Agency: HHS
Contract: 4R44HL072671-02
Award Amount: $1,029,846.00
 

Abstract:

DESCRIPTION (provided by applicant): Proposed in this Fast Track Phase I/Phase II proposal is the development of mass spectrometric immunoassays (MSIA) targeting apolipoproteins in human blood. Assays, utilizing antibody-derivatized affinity pipettes and MALDI-TOF mass spectrometry, will be developed for Apo-A, -C, -D, -E, -H and -J. These assays will have general use in studies investigating the quantitative modulation of, and point mutations and posttranslational modifications present in, the apolipoproteins. Phase I research will address the Specific Aim of optimizing affinity pipette chemistries for apolipoproteins. By reaching the Phase I milestone of high reproducibility, low non-specific binding qualitative assays (for the apolipoproteins when analyzed from small volumes (< 50 uL) of human blood), we will proceed into Phase II research. Phase II objectives include: 1) The use of enzymatically-active MALDI-TOF MS targets in conjunction with MSIA for structural characterization of the apolipoproteins, 2) The incorporation of quantitative methodologies into the assays, and 3) The development of a MSIA assay for common ApoE phenotypes. The final objective of the program is the development of kits and low-cost analytical platforms for the high-throughput analysis of apolipoproteins. Upon supply to the public, the approach will find initial applications in proteomic investigations linking protein variants with disease and potential long-term applications as phenotyping assay for use in clinical/diagnostic or drug administration applications.

Principal Investigator:

Randall W. Nelson
4088041778
RNELSON@INTRINSICBIO.COM

Business Contact:

Kemmons Tubbs
4808041778
KTUBBS@INTRINSICBIO.COM
Small Business Information at Submission:

INTRINSIC BIOPROBES, INC.
INTRINSIC BIOPROBES, INC. 625 S SMITH RD, STE 22 TEMPE, AZ 85281

EIN/Tax ID: 860842933
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No